Thymosin Alpha-1 Did Not Restore Immune Cell Counts or Speed Virus Clearance in COVID-19 Patients

Retrospective cohort study of 275 COVID-19 patients admitted to Shanghai Public Health Clinical Center. Patients were divided into Tα1-treated (n=126) and untreated (n=149) groups. Longitudinal T lymphocyte subset counts (CD4+ and CD8+) were compared between groups. Clinical outcomes including virus clearance duration were assessed. Multivariate linear regression controlled for confounders including illness severity.

Thymosin alpha-1 has been widely used in Asia as an immune-boosting peptide for infections and cancer. During the pandemic, it was administered to many COVID-19 patients based on its reputation for immune restoration. This study provides important negative evidence that challenges the assumed benefit, highlighting the critical need for controlled trials before adopting peptide therapies based on mechanism-of-action reasoning alone.

Thymosin alpha-1 is one of the most widely used therapeutic peptides globally, particularly in China for hepatitis B, immunodeficiency, and as a cancer adjuvant. Its use in COVID-19 represented a test of whether broad immunostimulation could help patients with infection-induced immune depletion. The negative results contribute to a growing understanding that immune modulation in acute viral infections is complex — boosting the immune system at the wrong time or in the wrong way may not help and could potentially cause harm.

This is a retrospective study, so patients receiving Tα1 may have been sicker at baseline (confounding by indication). The study was not randomized, limiting the ability to draw causal conclusions. The Tα1 dose, timing, and duration varied. Virus clearance was measured by PCR, which may not reflect clinical outcomes. Only T cell counts were assessed — other immune parameters that Tα1 might affect were not evaluated.